Literature DB >> 20882023

Therapy: Immunogenicity of biologic therapies-we need tolerance.

Charlotte L M Krieckaert, G Margret Bartelds, Gerrit-Jan Wolbink.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20882023     DOI： 10.1038/nrrheum.2010.153

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  10 in total

Review 1.  Dealing with immunogenicity of biologicals: assessment and clinical relevance.

Authors:  Gerrit J Wolbink; Lucien A Aarden; B A C Dijkmans
Journal:  Curr Opin Rheumatol       Date:  2009-05       Impact factor: 5.006

2.  Elimination of the immunogenicity of therapeutic antibodies.

Authors:  L K Gilliland; L A Walsh; M R Frewin; M P Wise; M Tone; G Hale; D Kioussis; H Waldmann
Journal:  J Immunol       Date:  1999-03-15       Impact factor: 5.422

3.  Infliximab, azathioprine, or combination therapy for Crohn's disease.

Authors:  Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

4.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

Authors:  Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2003-02-13       Impact factor: 91.245

5.  Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis.

Authors:  Geertje M Bartelds; Carla A Wijbrandts; Michael T Nurmohamed; Steven Stapel; Willem F Lems; Lucien Aarden; Ben A C Dijkmans; Paul Peter Tak; Gerrit Jan Wolbink
Journal:  Ann Rheum Dis       Date:  2007-02-14       Impact factor: 19.103

6.  A novel strategy to reduce the immunogenicity of biological therapies.

Authors:  Jennifer Somerfield; Grant A Hill-Cawthorne; Andrew Lin; Michael S Zandi; Claire McCarthy; Joanne L Jones; Michael Willcox; David Shaw; Sara A J Thompson; Alastair S Compston; Geoff Hale; Herman Waldmann; Alasdair J Coles
Journal:  J Immunol       Date:  2010-06-02       Impact factor: 5.422

7.  Optimization algorithms for functional deimmunization of therapeutic proteins.

Authors:  Andrew S Parker; Wei Zheng; Karl E Griswold; Chris Bailey-Kellogg
Journal:  BMC Bioinformatics       Date:  2010-04-09       Impact factor: 3.169

8.  Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.

Authors:  R N Maini; F C Breedveld; J R Kalden; J S Smolen; D Davis; J D Macfarlane; C Antoni; B Leeb; M J Elliott; J N Woody; T F Schaible; M Feldmann
Journal:  Arthritis Rheum       Date:  1998-09

9.  CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study.

Authors:  M E Weinblatt; P J Maddison; K J Bulpitt; B L Hazleman; M B Urowitz; R D Sturrock; J S Coblyn; A L Maier; W R Spreen; V K Manna
Journal:  Arthritis Rheum       Date:  1995-11

10.  Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Authors:  Alasdair J Coles; D Alastair S Compston; Krzysztof W Selmaj; Stephen L Lake; Susan Moran; David H Margolin; Kim Norris; P K Tandon
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245
  10 in total
  4 in total

1.  Paradoxical Expansion of Th1 and Th17 Lymphocytes in Rheumatoid Arthritis Following Infliximab Treatment: a Possible Explanation for a Lack of Clinical Response.

Authors:  Rossella Talotta; Angela Berzi; Fabiola Atzeni; Alberto Batticciotto; Mario Clerici; Piercarlo Sarzi-Puttini; Daria Trabattoni
Journal:  J Clin Immunol       Date:  2015-08-14       Impact factor: 8.317

2.  Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles.

Authors:  Takashi K Kishimoto; Joseph D Ferrari; Robert A LaMothe; Pallavi N Kolte; Aaron P Griset; Conlin O'Neil; Victor Chan; Erica Browning; Aditi Chalishazar; William Kuhlman; Fen-Ni Fu; Nelly Viseux; David H Altreuter; Lloyd Johnston; Roberto A Maldonado
Journal:  Nat Nanotechnol       Date:  2016-08-01       Impact factor: 39.213

3.  Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A.

Authors:  Ronit Mazor; Aaron N Vassall; Jaime A Eberle; Richard Beers; John E Weldon; David J Venzon; Kwong Y Tsang; Itai Benhar; Ira Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-03       Impact factor: 12.779

Review 4.  Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity.

Authors:  Karin A van Schie; Gerrit-Jan Wolbink; Theo Rispens
Journal:  MAbs       Date:  2015       Impact factor: 5.857
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.